AWM
ACOR

Apollon Wealth Management’s Acorda Therapeutics ACOR Stock Holding History

Apollon Wealth Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-750
Closed -$69K – 786
2021
Q3 		$69K Buy
+750
New +$62.2K 0.01% 461

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Apollon Wealth Management's ACOR Position: Q4 2021 in Review

Apollon Wealth Management sold out of Acorda Therapeutics (ACOR) in Q4 2021, closing a stake of 750 shares — an estimated $69K sold.

Apollon Wealth Management first reported a position in ACOR in Q3 2021 and held it in 1 quarter. The position peaked at $69K in Q3 2021. 32 funds tracked by Wall St. Rank hold ACOR as of Q4 2021.

  • Apollon Wealth Management reported no remaining Acorda Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Apollon Wealth Management sold 750 Acorda Therapeutics shares in Q4 2021, an estimated $69K.
  • Apollon Wealth Management first reported a position in Acorda Therapeutics in Q3 2021 and held it in 1 quarter.
  • Apollon Wealth Management's Acorda Therapeutics position peaked at $69K in Q3 2021.
  • 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2021.

Based on Apollon Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.